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3554ABSTRACT
In this study the authors evaluated the efﬁcacy of prophylaxis with liposomal amphotericin B
(L-AmB) in the incidence of fungal infections (FI) during the ﬁrst 3 months after liver
transplant (LT). The study was retrospective and accessed a 4-year period from 2008 to
2011. All patients who died in the ﬁrst 48 hours after LT were excluded. Patients were
divided by the risk groups for FI: Group 1, high-risk (at least 1 of the following conditions:
urgent LT; serum creatinine >2 mg/dL; early acute kidney injury [AKI] after LT; retrans-
plantation; surgical exploration early post-LT; transfused cellular blood components [>40
U]); and Group 2, low-risk patients. Group 1 patients were further separated into those who
received antifungal prophylaxis with L-AmB and those who did not. Prophylaxis with L-
AmB consisted of intravenous administration of L-AmB, 100 mg daily for 14 days. Four
hundred ninety-two patients underwent LT; 31 died in the ﬁrst 48 hours after LT. From the
remaining 461 patients, 104 presented with high-risk factors for FI (Group 1); of these, 66
patients received antifungal prophylaxis and 38 did not. In this group 8 FI were observed, 5
in patients without antifungal prophylaxis (P ¼ .011). Three more FI were identiﬁed in
Group 2. By logistic regression analysis, the categorical variable high-risk group was inde-
pendently related to the occurrence of invasive FI (P ¼ .006). We conclude that prophylaxis
with L-AmB after LT was effective in reducing the incidence of FI. No inﬂuence on mor-
tality was detected.*Address correspondence to Paulo Marcelino, Hospital Curry
Cabral, Rua da Beneﬁcência, 8, 1069-166 Lisboa. E-mail:
p.marcelino@netcabo.ptFUNGAL INFECTIONS (FI) are infections caused byfungi and can occur in any part of the body. After liver
transplantation (LT) and associated immunosuppression,
FI, particularly systemic invasive FI (IFI), can occur more
frequently and are regarded as the fourth most common
type of infections in this patient group [1,2]. The incidence,
although declining in recent years, may reach 40%, and
most importantly, IFI carry a high mortality that is reported
to be as high as 77% [3,4]. The most common pathogen is
Candida albicans, followed by Aspergillus sp. These FI occur
more frequently early after LT (up to 1 month), although
55% of Aspergillus sp infections occur in the ﬁrst year after
LT and 25% afterwards. Overall, FI due to Candida spp and
Aspergillus spp account for nearly 80% of all FI in these
patients.
It seems reasonable to prevent these infections using
appropriate antifungal agents. Ideally, they should be able4
.org/10.1016/j.transproceed.2014.06.065to treat the usual fungal pathogens in this group of patients,
thus preventing all fungal infections, particularly IFI, and
not interact with the common drugs used, as well as have an
adequate safety proﬁle. The most worrisome problems
relate to initial liver function and avoiding further renal
impairment.
Patient selection is another important issue. As the
administration of prophylaxis to all patients undergoing
LT is questionable, the most recent guidelines identify
high-risk groups, in whom the incidence of FI and IFI is
much higher [5]. Furthermore, the use of ﬂuconazole is
related to the emergence of mon-Candida spp, as well asª 2014 by Elsevier Inc. All rights reserved.
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LIPOSOMAL AMPHOTERICIN B & FUNGAL INFECTIONS 3555ﬂuconazole-resistant species [6]. Also, ﬂuconazole is not
active against Aspergillus spp.
The LT Center at Hospital Curry Cabral is the leading LT
center in the country. The main specialty is the performance
of sequential or domino LT, in which the liver explanted
from patients suffering from familial amyloidotic poly-
neuropathy (FAP) are transplanted to recipients suffering
from end-stage liver disease (ESLD). From 2007, liposomal
amphotericin B (L-AmB) was proposed as a prophylactic
agent in selected, high-risk LT patients. To test the efﬁcacy
of this prophylaxis, we performed a retrospective study on
this issue, recovering the data for 4 consecutive years of LT
and evaluating the incidence of IFI in high-risk patients,
divided by those who received prophylactic L-AmB and
those who did not.MATERIAL AND METHODS
All patients who underwent LT from January 2008 to December
2011 were considered for enrollment. Patients who died intra-
operatively and patients who died in the ﬁrst 48 hours after LT were
excluded. Patients were selected based on whether they were
deﬁned as high risk (Group 1) or low risk (Group 2). In Group 1,
patients were further separated into those who received antifungal
prophylaxis with L-AmB and those who did not. The incidence of FI
was then evaluated and compared in all patient groups (Group 1 vs
Group 2; and in Group 1, with and without prophylaxis). The
prophylaxis with L-AmB was performed as intravenous adminis-
tration of L-AmB, 100 mg daily for 14 days post LT. This
administration started in 2007, but only became part of the protocol
in 2012, so not all high-risk patients received it. All patients who
undergo LT in our center also receive oral nystatin every 6 hours,
and women receive vaginal clotrimazole once a day.
The high-risk group was deﬁned by the presence of at least 1 of
the following conditions: urgent LT due to acute liver failure or
acute-on-chronic liver failure; serum creatinine >2 mg/dL previous
to LT or hemodialysis previous to LT; early acute kidney injury
(AKI) after LT with need for renal replacement technique;
retransplantation; early post-LT need for surgical reintervention
(mainly due to vascular complications and bleeding); transfused
cellular blood components (red blood cell packed units [RBC] and
platelet units >40 U) during LT.
Any fungal isolates were regarded as FI, whereas IFI was deﬁned
as proven or probable fungal infection in any body site or ﬂuid
obtained from a normally sterile site. Other isolates from non-
sterile sites were considered non-invasive candidiases. [7,8].
The data collected for comparative purposes were the recipients’
age and gender; surgery duration; duration of cold ischemia; pre-LT
Model for End-stage Liver Disease (MELD) and Child-Turcotte-
Pugh (CTP) scores; development of AKI after LT (using the AKI
classiﬁcation); hemodynamic instability during surgery (deﬁned as
the continuous infusion of vasopressor for more than 5 minutes);
maximum alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) levels after LT; number of RBC and fresh frozen
plasma (FFP) units transfused during surgery; intensive care unit
(ICU) and hospital stay; and type of LT (deceased-donor LT or
sequential LT). The study period was extended for 3 months after
transplantation. Occurrence of drug-related toxicity also was
evaluated.
Deceased-donor liver grafts were harvested from brain-dead,
heart-beating donors (the majority from other Portugueseinstitutions), preserved in Celsior solution and implanted in the
recipient using the piggyback technique. In domino liver trans-
plantation (DLT), the native hepatectomy in FAP patients, and the
implantation of the deceased-donor graft also were done in standard
piggyback fashion, with retrohepatic vena cava preservation and
without venovenous bypass. FAP livers also were ﬂushed with and
preserved in the Celsior solution. As FAP liver grafts were harvested
without the vena cava, the hepatic venous outﬂow of the domino
grafts was reconstructed on the back table, using a vein graft from the
deceased donor as previously described [9]. Following the recon-
struction of hepatic venous outﬂow, the portal vein, hepatic artery,
and bile duct were anastomosed.
The usual immunosuppressive therapy in use in our center con-
sists of prednisolone, at a dose of 3 mg/kg i.v. in the ﬁrst days,
decreasing by 20 to 30 mg each day until reaching the maintenance
dosage of 20 mg/day; mycophenolate mophetil 500 mg bid
(according to platelet and white blood cell count); calcineirin
inhibitors (CNI, cyclosporine A, 8 mg/kg/day; or tacrolimus, 0.1 mg/
kg/day), to attain a target serum level of 350e400 ng/mL for
cyclosporine A and 8e12 ng/mL for tacrolimus. Patients with renal
impairment previous to LT received basiliximab 4 mg in the ﬁrst day
and 4 mg in the fourth postoperative day; in these patients, CNI is
introduced after 7 days. All prescriptions are given by the
hepatologist.
Before LT all patients must sign an informed consent document.
Our protocol for data collection was reviewed and approved by the
institutional ethic board.
Continuous variables are expressed as an average and standard
deviation. Categorical variables are presented as categories with
percentages. For comparative analysis, parametric (Student t test,
for numeric variables, after conﬁrmation of the normal distribution
of data by the Kolmogorov-Smirnov test) and nonparametric tests
(c2 test or Fisher’s exact test, for categorical variables) were used.
To establish dependence between variables, logistic regression
analysis was performed (backward LR), using variables that were
signiﬁcant on univariate analysis, and a goodness-of-ﬁt test
(Hosmer-Lemeshow) was used to assess the ﬁt of the logistic
regression model. The dependent variable considered was the
occurrence of FI when comparing patients in Group 1 who received
prophylaxis with those who did not. A logistic regression analysis
also was performed to establish the dependence of FI occurrence
(FI as dependent variable) on the evaluated parameters. A P
value <.05 was considered statistically signiﬁcant. Statistical analysis
was performed using SPSS 19.0 (Statistical Package for Social Sci-
ences, SPSS Inc., Chicago, Ill., United States).RESULTS
In the study period, 492 patients underwent LT. Of these, 31
died either during surgery or in the ﬁrst 48 hours after LT
and were excluded. Of the remaining 461 patients, 104
presented high-risk factors for FI (Group 1) and the other
357 did not (Group 2). Group 1 patients presented the
following risk factors: acute liver failure or acute-on-chronic
liver failure (23 patients); serum creatinine >2 mg/dL
previous to LT or hemodialysis previous to LT (18 patients);
early AKI after LT with need for renal replacement
technique (7; with 17 patients developing AKI 3); retrans-
plantation (16 patients); early post-LT need for surgical
reintervention (mainly due to vascular complications and
bleeding) (39 patients); and transfused cellular blood
3556 ANTUNES, TEIXEIRA, CORVO ET ALcomponents (red blood cell packed units [RBC] and platelet
units >40 U) during LT (26 patients).
The characteristics of these groups are compared in
Table 1. Group 1 patients had hemodynamic instability
more often during surgery, as well as more severe AKI after
LT; also, their MELD and CTP scores were higher. Dura-
tion of surgery was greater in group 1, although the duration
of cold ischemia did not differ signiﬁcantly.
In the high-risk group, 66 patients received antifungal
prophylaxis and 38 did not. The comparative characteristics
of these patients are presented in Table 2. The only dif-
ference between these groups is the number of required
blood transfusions. Otherwise, they were similar in the
studied parameters.
A total of 11 FI were identiﬁed (2.5% incidence in the
cohort), 8 in the high-risk group (7% incidence). An FI was
detected in 3/66 (4.5%) patients who received prophylaxis
with L-AmB and in 5/38 (13.1%) patients who did not
(P ¼ .011). The FI detected were as follows: 2 biliary and 1
esophageal candidiasis in patients who received prophylaxis;
and 3 esophageal, 1 candidemia, and 1 biliary in patients
who did not receive prophylaxis. Seven isolates were
C. albicans, and 1 was Candida tropicalis (a biliary candidi-
asis in a patient from the group that received prophylaxis).
In low-risk patients 3 FI were observed: an esophageal and
biliary, all C. albicans, and a Candida parapsilosis in the
bloodstream. The average time from LT until the detection
of IFI in the high-risk group was 27.8 days (minimum 6 days,
maximum 81 days; with only 2 patients after 1 month).
After the 3-month period of the study and until the ﬁrst
year after LT another 9 FI were detected. Within the high-Table 1. Patient Characteristics, Separate
High-Risk Group
Age (years, mean and SD) 47.8 
Male (n and %) 81 (7
Main pathologies (n and %)
Acute liver failure 16 (1
Compensated cirrhosis 65 (6
FAP 11 (1
Other 12 (1
Deceased-donor recipients (n and %) 95 (9
MELD score (mean and SD) 15.6 
CTP score (mean and SD) 7.1 
Operative time (min, mean and SD) 344 
Cold ischemia time (min, mean and SD) 377 
Maximum ALT (IU, mean and SD) 2499 
Maximum ALT (IU, mean and SD) 1451 
Hemodynamic instability during surgery (n and %) 55 (
RBC (units, mean and SD) 7.6 
FFP (units, mean and SD) 21.9 
Mean AKI score (mean and SD) 1.3 
ICU stay (days, mean and SD) 5.2 
Hospital stay (days, mean and SD) 27.2 
Mortality (at 3 months) 13 (1
Abbreviations: SD, standard deviation; FAP, familial amyloidotic polyneuropathy; M
aminotransferase; AST, aspartate aminotransferase; IU, international units; RBC, red b
unit.risk group, FI were detected in 4 patients of the group who
received prophylaxis (3 oral candidiasis and 1 vaginal); and
1 oral candidiasis in the group who didn’t receive prophy-
laxis. In the low-risk group from the 3rd to 12th month, 6 FI
were observed: 2 urinary, 1 vaginal, and 3 oral candidiasis.
In the low-risk group, 6 noninvasive fungal infections were
observed: 2 urinary, 1 vaginal, and 3 oral candidiasis.
By logistic regression analysis, considering the entire
cohort and IFI regarded as a dependent variable, only the
variable high-risk group presented an independent relation
to the occurrence of FI (P ¼ .006, conﬁdence interval
3.6e18.5).
In 1 patient, prophylaxis with L-AmB was discontinued
due to a rise in serum creatinine levels.DISCUSSION
The present study veriﬁed that antifungal prophylaxis with
L-AmB was effective in reducing the incidence of FI in high-
risk patients undergoing LT.
There are several descriptions of similar use of this drug
in antifungal prophylaxis after LT in high-risk patients.
However, the cohorts vary in dimension, time, and dosing
regimens. Also, the majority of the available studies were
published more than a decade ago. The study by Mora et al
[10] used conventional amphotericin B in a dose of 1 mg/kg
during 5 days; the study by Braun et al [11] used different
doses of L-AmB, from 1 to 5 mg/kg until the discharge from
the ICU); Lorf et al [12] used a dose of 5 mg/kg/day of L-
AmB for 7 days; Castroagudin et al [13] used a dose of 1 mg/
kg L-AmB for 7 to 10 days. Nonetheless, all these studiesd by Risk of Invasive Fungal Infection
(Group 1, n ¼ 104) Low-Risk Group (Group 2, n ¼ 357) P Value
13.1 46.5  12.7 ns





1.3%) 109 (30.5%) <.001
4.7 13.1  3.8 .001
2.4 6.1  3.1 .028
68.5 311.2  55.1 .001
66.3 368.9  61.9 ns
3013 2152  2658 ns
1316 1481  1574 ns
52%) 65 (18.2%) <.001
4.8 3  3.1 <.001
12.9 9.2  8.7 <.001
1.2 0.6  0.9 <.001
3.1 2.1  2.2 <.001
11.2 17.1  8.2 .001
2.5%) 10 (2.9%) <.001
ELD, Model for End-stage Liver Disease; CTP, Child-Turcotte-Pugh; ALY, alanine
lood cell; FFP, fresh frozen plasma; AKI, acute kidney injury; ICU, intensive care
Table 2. High-risk Patient Characteristics, Separated by Those Who Received Antifungal Prophylaxis and Those Who Did Not
Received Antifungal Prophylaxis (n ¼ 66) Did Not Receive Antifungal Prophylaxis (n ¼ 38) P Value
Age (years, mean and SD) 48.4  13.8 46.6  11.7 ns
Male (n and %) 29 (64.4%) 21 (56.8%) ns
Main pathologies (n and %)
Acute liver failure or acute on chronic liver failure 12 (18.2%) 4 (10.5%)
Retransplantation 12 (18.2%) 4 (10.5%)
AKI or HD 17 (25.7%) 8 (21.0%)
Other 25 (37.8%) 22 (58.0%)
Deceased-donor recipients (n and %) 21 (56.8%) 23 (73.3%) ns
MELD score (mean and SD) 16.1  4.7 15.2  4.4 ns
CTP score (mean and SD) 7.1  2.3 7.2  2.7 ns
Operative time (min, mean and SD) 348  67.5 337  72.8 ns
Cold ischemia time (min, mean and SD) 383  73.4 362  51 ns
Maximum ALT (IU, mean and SD) 2144  1671 2958  793 ns
Maximum ALT (IU, mean and SD) 1378  1156 1577  1544 ns
Hemodynamic instability during surgery (n and %) 44 (69.8%) 12 (52.2%) ns
RBC (units, mean and SD) 8.2  4.8 5.8  4.4 .001
FFP (units, mean and SD) 23.7  12.9 16.9  11.7 ns
Mean AKI score (mean and SD) 1.2  1.3 1.3  1.1 ns
ICU stay (days, mean and SD) 5.4  3 5.1  3.4 ns
Hospital stay (days, mean and SD) 25.8  11.4 27.4  10.9 ns
Mortality 8 (12.1%) 5 (13.1%) ns
Occurrence of IFI 3 (4.5%) 5 (13.1%) .011
Abbreviations: SD, standard deviation; FAP, familial amyloidotic polyneuropathy; MELD, Model for End-stage Liver Disease; CTP, Child-Turcotte-Pugh; ALY, alanine
aminotransferase; AST, aspartate aminotransferase; IU, international units; RBC, red blood cell; FFP, fresh frozen plasma; AKI, acute kidney injury; ICU, intensive care
unit; IFI, invasive fungal infection; HD, hemodialysis.
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groups. In the present study we used a ﬁxed dose of 100
mg/day L-AmB, roughly 1.5 mg/kg/day. At this dosage, it
was observed by Singh and Paterson [14] that FI due to
Aspergillus fumigatus can occur, thus suggesting higher doses
for prophylaxis. No Aspergillus spp was identiﬁed during the
study period. Moreover, only 2 systemic FI were detected, a
lower than expected incidence. Other FI, namely oral,
vaginal, and urinary, were not detected during the study
period, although some occurred later. Perhaps, some role
can be attributable to local antifungal prophylaxis with
nystatin and clotrimazole.
Biancaﬁori et al [15] observed that not all patients un-
dergoing LT beneﬁt from antifungal prophylaxis using
L-AmB as prophylactic drug. However, the deﬁnition of
high-risk group, although important in patient selection, can
also differ among studies. Despite these differences, the risk
factors are now better characterized, and new scoring
systems like MELD have entered clinical practice [16]. In
our study we found differences between high- and low-risk
groups in MELD and CTP score and operative time.
Interestingly, cold ischemia time and data regarding early
graft injury did not differ. Not surprisingly, the need for
hemodynamic support and AKI development was higher in
the high-risk group. In the low-risk group, more patients
received grafts harvested from FAP patients. This data
should be taken with caution. The high-risk group included
patients with acute liver diseases, who underwent LT
urgently. The FAP livers are preferentially allocated to
patients with neoplastic diseases and stable liver cirrhosis.Nonetheless, these grafts are successfully transplanted with
fewer postoperative complications, as described earlier [17].
We should note that the local conditions and speciﬁc
agents may vary from center to center. In fact, during this
extended period of observation, in our center only
Candida spp was identiﬁed. Moreover, no Candida glab-
rata was isolated, thus characterizing the speciﬁc envi-
ronment for fungal infections. This fact must be taken in
consideration when analyzing the speciﬁc antifungal pro-
phylaxis and treatment in different centers and countries.
Taking this in consideration, the comparison between
centers may be difﬁcult.
The time for FI occurrence also agrees with that
described in the literature [18]. Moreover, there was no
death that could be attributable to FI, so this antifungal
prophylaxis may contribute to the decrease in FI after LT,
but not to mortality reduction, as sensed by several authors.
The overall incidence of FI was lower than described
(2.5% in the entire cohort; 7% in the high-risk group). This
fact may be related to the time period studied (2008 to
2011). Several conditions, such as improved surgical tech-
nique and better patient selection, are well described as
inﬂuencing the incidence of fungal infections.
Several studies evaluated the use of amphotericin B
lipid complex (ABLC) [19e22], using different doses
(from 1 mg/kg/day to 5 mg/kg/day) and different times. In
this study, the drug used was the liposomal formulation of
AmB. We note that in some studies address ABLC and L-
AmB as lipid formulations interchangeably and do not
distinguish one from the other [23]. It may be useful to
3558 ANTUNES, TEIXEIRA, CORVO ET ALrecall some differences between them. The clinical use of
this antifungal agent was precluded by their toxic effects
[24]. One successful strategy used in the 1980s was the
incorporation of these drugs in liposomes [25], lipid-based
vesicles of concentric phospholipid bilayers separating
water compartments. Several clinical studies have
demonstrated that AmB was effective and less toxic than
free AmB in the treatment of fungal infections. In 1995,
after developing a new formulation of the previously
described L-AmB, an amphotericin B lipid complex was
described. It should be noted that all the lipid-based
formulations of amphotericin B differ in their physico-
chemical properties in terms of size, lipid composition,
shape, surface charge, drug-to-lipid ratio, and stability.
With all these differences it is expected that their in vivo
behavior will be different in terms of dosage, treatment
schedule etc, as they are cleared differently and with
different mechanisms from circulation [25e28]. There-
fore, although the drug is the same, its pharmacology is
different, and the appropriate dose must be carefully
evaluated, deﬁning a prophylaxis dosage and a therapeu-
tic dosage. Nonetheless, all studies using lipid complex
with amphotericin B also demonstrated to be efﬁcacious
in preventing IFI after LT.
Study Limitations
As pointed by some authors, the strength of a retrospective
study is not comparable to that of a prospective, random-
ized, controlled study. The majority of the studies in this
ﬁeld are retrospective and use historical controls, so our
study shares these deﬁciencies with most studies in the
literature. The spectrum of antifungal therapy is now wide.
No comparison between drugs was performed, although
several other antifungal agents were successfully tested as
prophylactic agents after LT.
The identiﬁcation of FI is now supported by the use of
molecular diagnosis, which we did not test. The use of this
information may be included in future work.
CONCLUSION
Prophylaxis with L-AmB 100 mg daily for 14 days after LT
was found to be effective in preventing IFI in high-risk
patients after LT. The overall incidence of FI was 2.5%
and 7% in the high-risk group. In this 4-year period, only
Candida sp was detected, mainly C. albicans. No individual
risk factor for IFI was superior. The accurate dose and
prophylaxis time remain to be evaluated, considering local
factors and most common isolates, which may vary from
center to center.
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